EichorEICHOR
Condition: Recurrent Grade Iii Glioma Synced from ClinicalTrials.gov · August 07, 2026

Recruiting studies: Recurrent Grade Iii Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astr
Phase 1 · 43 location(s) · National Cancer Institute (NCI) · NCT06860594Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1 · 1 location(s) · Northwestern University · NCT06410248Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) in Glioma (WHO G3-G4) Progression
NA · 2 location(s) · Medical University of Warsaw · NCT06975332Combination Therapy for the Treatment of Diffuse Midline Gliomas
Phase 2 · 32 location(s) · University of California, San Francisco · NCT05009992A Clinical Trial Evaluating the Tolerability, Safety, and Preliminary Efficacy of NRG-103 Injection in Patients With Rec
Phase 1 · 3 location(s) · Neuregen Therapeutics Co., Ltd. · NCT07710690An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Gliom
Phase 2 · 1 location(s) · Mayo Clinic · NCT06444412Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
Phase 1 · 1 location(s) · Susan Chang · NCT04540107Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment
Phase 2 · 27 location(s) · National Cancer Institute (NCI) · NCT05859334Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
Phase 1 · 1 location(s) · Beijing Tiantan Hospital · NCT06253234Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progress
Phase 1 · 1 location(s) · City of Hope Medical Center · NCT06815029A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma
Phase 1/Phase 2 · 16 location(s) · Debiopharm International SA · NCT05765812Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT06964737A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Gliobl
Phase 1 · 2 location(s) · University of Florida · NCT04573140HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM
Phase 1/Phase 2 · 1 location(s) · David Baskin MD · NCT03596086ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
Phase 1 · 7 location(s) · Sabine Mueller, MD, PhD · NCT04732065Study of Pembrolizumab and M032 (NSC 733972)
Phase 1/Phase 2 · 1 location(s) · University of Alabama at Birmingham · NCT05084430
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.